Company News - VC and PE investment business - Medical and health professional investment - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 07 - 30

Efung Capital Honored with Three Accolades at the 9th Healthcare Investment Excellence Awards

On July 30, 2025, Hao Yue Capital officially released the "9th Healthcare Investment Excellence Awards." Efung Capital was recognized as "Best Early-Stage Healthcare Investment Institution of the Year" and "Best Innovative Pharmaceutical Investment Institution of the Year." Mr. Zhu Pui, CEO of Efung Capital, was honored as "Young Healthcare Investor of the Year."Now in its ninth year, the "Healthcare Investment Excellence Awards," meticulously established by Hao Yue Capital, continue to be grounded in the principles of "fairness, justice, ...

浏览次数：0

查看详情>>

发布时间: 2025 - 07 - 29

All About "Liver"! World Hepatitis Day – 3 Minutes to Master Liver Protection Tips | Efung Knowledge

On July 28, 2025, amidst the rising chorus of summer cicadas, we welcome a day filled with care – the 15th "World Hepatitis Day."This year, China's theme is "Social Co-governance to Eliminate Hepatitis," like a gentle ray of sunshine, calling on us to slow down and pay collective attention to lives silently enduring the pain of illness. Let us join hands to convey understanding and hope, infusing warm strength into the effort to eliminate the harm caused by hepatitis.01 Current Status and Challenges of Viral HepatitisIn China, the prevention and control of viral hepatit...

浏览次数：1

查看详情>>

发布时间: 2025 - 07 - 22

Three Portfolio Companies Selected! The GEI China Unicorn Enterprise Research Report 2025 and Shenzh

On July 18, 2025, the 2025 China (Shenzhen) Unicorn Enterprise Conference, themed "New Quality Driven • Future Navigation," was held in Shenzhen. The GEI China Unicorn Enterprise Research Report 2025 and the Shenzhen Unicorn Enterprise and Gazelle Enterprise Research Report 2025 were simultaneously released, revealing the current status and trends of unicorn enterprise development in China and Shenzhen.The reports show that since 2024, the Shenzhen Small and Medium Enterprises Service Bureau has established a Shenzhen Gazelle and Unicorn Enterprise Evaluation Committee to select and ...

浏览次数：0

查看详情>>

发布时间: 2025 - 07 - 18

Oryzogen's Plant-Derived Recombinant Human Serum Albumin Injection Approved for Marketing

On July 18, the Plant-Derived Recombinant Human Albumin Injection, developed by Wuhan Oryzogen Biotechnology Co., Ltd. using "rice-sourced hematopoiesis" technology, was officially approved for marketing for the treatment of hypoalbuminemia (≤30g/L) associated with liver cirrhosis. Upon market launch, this product will become the first human serum albumin injection in China developed using recombinant protein technology.Currently, human serum albumin drugs used in clinical practice are all derived from human plasma through separation and extraction, which carries risks of resource sh...

浏览次数：0

查看详情>>